Jeffrey Hammerbacher has officially filed a Form 3, indicating his position as a director at Roivant Sciences Ltd. This filing is significant as it reflects the ongoing governance and regulatory compliance within the pharmaceutical preparations industry.

Roivant Sciences Ltd., incorporated in the United Kingdom, focuses on advancing drug development and has been recognized for its innovative approach in the pharmaceutical sector. The company is listed under the Central Index Key (CIK) 0001635088.

The filing states that Hammerbacher does not currently own any securities beneficially. The document notes, "No securities are beneficially owned." It also highlights that Hammerbacher is a director but not an officer or a ten percent owner of the company.

This update may affect Roivant's strategic direction and corporate governance, as Hammerbacher's involvement could influence decision-making processes within the company. The filing was made under the Securities Exchange Act of 1934, which emphasizes the importance of transparency in corporate governance.

The filing does not say what happens next, leaving the future actions of Hammerbacher and Roivant Sciences open to speculation.

Filing Details

The Form 3 was filed on November 19, 2026, with a reporting period ending on November 9, 2026. This document is crucial for maintaining compliance with the Securities Exchange Act of 1934, which governs the reporting of securities ownership by directors and officers.

Hammerbacher's filing indicates that he is a director of Roivant Sciences Ltd., but does not hold any beneficial ownership of securities at this time. The filing also specifies that he is neither an officer nor a ten percent owner of the company, which may impact his influence on corporate decisions.

Power of Attorney

Additionally, the filing includes an Exhibit 24, which is a Power of Attorney document. This document designates Matthew Gline, Richard Pulik, and Sam Kaplan as attorneys-in-fact for Hammerbacher, allowing them to execute Forms 3, 4, and 5 on his behalf. This arrangement ensures that Hammerbacher can fulfill his reporting obligations under the Exchange Act without personally executing each document.

The Power of Attorney remains in effect until Hammerbacher is no longer required to file these forms, unless revoked earlier. This provision highlights the importance of compliance and the delegation of responsibilities within corporate governance.

"The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act."

Company Information

Roivant Sciences Ltd. is categorized under the Standard Industrial Classification for Pharmaceutical Preparations, indicating its focus on drug development. The company is incorporated in the United Kingdom and has a fiscal year that ends on March 31. Its business address is located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom.

As of this filing, there is no indication of any upcoming changes or developments regarding Hammerbacher's role or the company's strategic initiatives, leaving the future direction of Roivant Sciences somewhat uncertain.